Shionogi and Ferrer conclude a contract for the promotion in Spain of▼ Rizmoic® (naldemedine), a therapeutic agent for opioid-induced constipation
Shionogi and Molteni conclude a contract for the commercialisation of Rizmoic® (naldemedine) an Opioid Induced Constipation (OIC) therapeutic agent in Italy and Poland
Shionogi Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
Medical NewsShionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019.pdf
Medical NewsShionogi to present clinical data on lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the LIiver (EASL)
EMA accepts MAA submission of Shionogi's naldemedine for the treatment of Opioid Induced Constipation
FDA approves Symproic (naldemedine) once-daily tablets C-II for the treatment of Opioid-Induced Constipation in Adults with chronic non-cancer pain
Naldemedine phase 3 study shows significant improvement for patients with Opioid-Induced Constipation
Shionogi announces its participation in an innovative new joint research initiative, The Cambridge Therapeutics Consortium
Shionogi receives Marketing and Manufacturing approval in Japan for MULPLETA Tablets 3mg for Improvement of Thrombocytopenia
Naldemedine meets primary endpoint in Phase 3 study for the treatment of opioid-induced constipation
Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi Italy
Shionogi announces that Naldemedine met the primary endpoint in it's first Japanese phase III study for the treatment of opioid-induced constipation in cancer patients
Shionogi & Co., Ltd announces that Naldemedine meets the primary endpoint in a Phase 3 study for the treatment of opiod-induced constipation
Medical News13.09.2013 - Data from the FLAMINGO Phase IIIb Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare
Medical News04.09.2013 - Shionogi Launches “IRTRA® Combination Tablets LD/HD” for the Treatment of Hypertension
Medical News13.08.2013 - ViiV Healthcare Receives FDA approval for the HIV Integrase Inhibitor Tivicay® (Dolutegravir)
Medical News28.06.2013 - Shionogi Receives Manufacturing and Marketing Approval for “IRTRA® Combination Tablets LD/HD” for the Treatment of Hypertension
07.05.2013 - Shionogi Inc. Divests and exclusively licenses its paediatric products to Concordia Pharmaceuticals Inc.
26.03.2013 - Shionogi Enters into Settlement Agreement with Generic Manufacturers over Crestor® Patent
Medical News25.03.2013 - Shionogi Receives Marketing and Manufacturing Approval of a Drug for Lipodystrophy, "METRELEPTIN for Subcutaneous Injection 11.25 mg 'SHIONOGI'"
Medical News07.03.2013 - Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
Medical News26.02.2013 - Shionogi receives FDA approval for Osphena (Ospemifene) for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause
Medical News18.02.2013 - U.S. Food and Drug Administration Priority Review Designation for HIV Integrase Inhibitor "Dolutegravir"
Medical News18.12.2012 - ViiV Healthcare Files a New Drug Application for the Integrase Inhibitor "Dolutegravir"
Medical News14.11.2012 - Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
Medical News31.10.2012 - Shionogi Enters into a License and Collaboration Agreement for Its Oral beta-Secretase Inhibitor Program for the Treatment of Alzheimer's Disease with Janssen Pharmaceuticals, Inc.
29.10.2012 - Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio
24.10.2012 - Ezose sciences forms alliance with fast forward to discover biomarkers to diagnose multiple sclerosis
01.10.2012 - Shionogi Announces the Conducting of an International Industry-academic Collaboration, Shionogi Science Program 2012, and a Drug Discovery Competition, FINDS 2012
31.08.2012 - Memorandum Signed with Five Danish Universities for Collaboration in Research and Development
Medical News10.08.2012 - Antitrichomonal Agent, Flagyl® Approval for Additional Indication for Amoebic Dysentery, Giardiasis, Anaerobic Infection and Infectious Enteritis
Medical News10.08.2012 - Synthetic Antibacterial Agent, Baktar® Approval for Additional Indication of Prophylaxis and Treatment for Pneumocystis pneumonia
Medical News08.08.2012 - Ildong Pharmaceutical Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet
Medical News01.08.2012 - Shionogi Filed a New Drug Application for Recombinant Human Leptin for Lipodystrophy
Medical News30.07.2012 - Shionogi Files an Application for an Anti-hypertension Drug "S-474474", a Combination of Irbesartan and Trichlormethiazide
Medical News26.07.2012 - Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1
Medical News11.07.2012 - Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Medical News28.06.2012 - U. S. Food and drug administration accepts Shionogi ospemifene new drug application in vulvar and vaginal atrophy
Medical News28.05.2012 - Shionogi Launches Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
Medical News25.05.2012 - Shionogi Receives Approvals of Paediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic,"Finibax® 0.25g/0.5g for Intravenous Drip Infusion" and "Finibax® 0.25g Kit for Intravenous Drip Infusion"
Medical News26.04.2012 - Shionogi files a new drug application for ospemifene oral tablets 60mg for the treatment of vulvar and vaginal atrophy
Medical News02.04.2012 - Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV
30.03.2012 - Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines
Medical News21.03.2012 - Anticancer Agent, Ifomide®, Approval of Additional Indication of Malignant Lymphoma
Medical News21.03.2012 - Antitrichomonal Agent, Flagyl®, Approval for Additional Indication of Bacterial Vaginosis
Medical News22.02.2012 - Serotonin/Noradrenalin Reuptake Inhibitor Cymbalta® Capsule 20 mg, 30mg Approval of Additional Indication for Diabetic Neuropathic Pain
Medical News25.01.2012 - Study data show Cuvposa® reduced chronic severe drooling in patients ages 3-16 years-old with neurologic conditions.
Medical News18.01.2012 - Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, "OxiFast® Injection 10mg" and "OxiFast® Injection 50mg"
Medical News29.11.2011 - Shionogi Launches Carbapenem-Type Antibiotic,"Finibax® 0.5g for Intravenous Drip Infusion"
18.11.2011 - Shionogi and Shire to Collaborate on the Development and Commercialization of the Therapeutic Agents for Attention-Deficit/Hyperactivity Disorder
03.10.2011 - Shionogi Announces the Conducting of International Industry-Academic Collaboration, SHIONOGI Science Program, and Drug Discovery Competition, FINDS2011
31.08.2011 - Shionogi & Co., Ltd. to Commence a General Offer for China-based C&O Pharmaceutical Technology (Holdings) Limited
18.08.2011 - Shionogi & Co., Ltd. to Acquire the Shares and to Conduct a General Offer for China-based C&O Pharmaceutical Technology (Holdings) Limited
01.08.2011 - Shionogi & Co., Ltd. to Acquire China-based C&O Pharmaceutical Technology (Holdings) Limited
Medical News22.04.2011 - Shionogi Receives Approval of Additional Dosage and Administration of Carbapenem Antibiotic Products: Finibax® 0.25g IV Solution and Finibax® 0.25g IV Solution Kit
Medical News07.04.2011 - Shionogi Announces Commercial Availability of CUVPOSA (glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated with Neurologic Conditions
01.04.2011 - Shionogi Signs Agreement with Denmark on International Industry-Academic Collaboration Initiatives
Medical News03.02.2011 - Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy
Medical News10.01.2011 - Shionogi Inc. Announces Commercial Availability of KAPVAY (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
28.10.2010 - Shionogi and GlaxoSmithKline to collaborate on the research, development and commercialisation of novel antibiotics targeting drug-resistant Gram-negative bacteria
Medical News27.10.2010 - Shionogi Receives an Approval for an Additional Indication for Paediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza
Medical News21.10.2010 - Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor
15.10.2010 - Shionogi Signs Agreement with Sweden on International Industry-Academic Collaboration Initiatives
Medical News04.10.2010 - Shionogi announces FDA approval of kapvay - the first and only therapy approved for use with stimulant medication for the treatment of ADH
Medical News29.07.2010 - Shionogi Inc. Announces FDA approval of cuvposa for the treatment of chronic severe drooling in paediatric patients with neurologic conditions
Medical News23.07.2010 - Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference
01.06.2010 - Shionogi Announces the Conducting of Drug Discovery Competition FINDS2010 -Drug seeds fostering type
Medical News02.03.2010 - Shionogi enters into exclusive license agreement with Quatrx Pharmaceuticals to market Ospemifene
Medical News15.02.2010 - Shionogi Files an Additional Application for Paediatric Use of “RAPIACTA®” a Novel Anti-viral Drug for Influenza
Medical News26.01.2010 - A Novel Anti-viral Drug for Influenza,“Rapiacta 300mg Bag for Intravenous Drip Infusion” and “Rapiacta 150mg Vial for Intravenous Drip Infusion” Launch
Medical News20.01.2010 - Shionogi Receives Marketing and Manufacturing Approval of an Antidepressant Drug,“Cymbalta ®Capsules 20mg and 30mg”